CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart FailureMay 22, 2013 11:00 am | by The Associated Press | News | Comments
PARIS & MENLO PARK, Calif.--(BUSINESS WIRE)--May 22, 2013--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based Parachute ® Ventricular Partitioning Device....
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effects. A new study from MIT analyzes the potential usefulness of a new treatment that combines the benefits of angioplasty balloons and drug-releasing stents, but may pose fewer risks.
BioVentrix to Exhibit Revivent™ System, which Surpasses Survival Benefit Threshold for Heart Failure Treatment, at European Heart Failure CongressMay 22, 2013 8:30 am | by The Associated Press | News | Comments
LISBON, Portugal--(BUSINESS WIRE)--May 22, 2013--BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure (HF), announced today that it will showcase its Revivent™ Myocardial Anchoring System at the European Heart Failure Congress (HFC)...
St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice SessionMay 21, 2013 9:52 am | by The Associated Press | News | Comments
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 21, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and...
Economic Model of the Life-time Cost Impact of Heart Valve Prosthetic Choice to be Presented at ISPOR MeetingMay 21, 2013 9:00 am | by The Associated Press | News | Comments
AUSTIN, Texas--(BUSINESS WIRE)--May 21, 2013--On-X® Life Technologies, Inc. (On-X LTI) announced today that a cost analysis entitled, “Initial Heart Valve Replacement Prosthetic Choice Has Long-Term Complications and Cost Impact: A Comparative Analysis,” will be presented in poster form at the...
MAQUET Cardiovascular Acquires LAAx Inc. and Its TigerPaw System II Occlusion Device to Expand Cardiac Surgery OfferingMay 21, 2013 8:00 am | by The Associated Press | News | Comments
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has acquired LAAx Inc., a privately held company that has developed a unique mechanical occlusion device called the TigerPaw@ System II ("TigerPaw II"). When implanted, TigerPaw II safely and...
VerrataT Pressure Guide Wire and iFR@ (Instant Wave-Free RatioT) Software Modality will be on display at EuroPCR 2013May 21, 2013 4:40 am | by The Associated Press | News | Comments
Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will demonstrate the VerrataT Pressure Guide Wire and the iFR@ (Instant...
Medtronic Finds TAVI with CoreValve System Cost Effective for Treating Patients with Severe Aortic StenosisMay 21, 2013 4:06 am | by The Associated Press | News | Comments
Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical management. Presented at EuroPCR 2013, the United Kingdom-based analysis compared the "real world" Medtronic CoreValve ADVANCE study to the medical management cohort of the PARTNER B study.
Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications. But compared to other central venous catheters, these commonly-used catheters more than double the risk of dangerous blood clots – especially among patients who are critically ill or who have cancer.
The study comprised over 24,000 Finnish subjects and was led by Professor Samuli Ripatti. The results revealed that a panel of 28 genetic markers improved detection of individuals with high risk for coronary heart disease (CHD) (10-year risk ≥20%) over traditional risk factors.
New Diagnostics Solutions from Welch Allyn to Help Improve Patient Safety, Reduce Risk for FacilitiesMay 20, 2013 11:05 am | by Welch Allyn | News | Comments
Welch Allyn, a leading medical diagnostic device company that specializes in helping clinicians improve patient outcomes, will showcase its new FlexiPort® EcoCuffTM blood pressure cuff and EarlySense Vitals Surveillance System at the National Teaching Institute & Critical Care Exposition this week at the Boston Convention & Exhibition Center in Boston, Mass.
BioMatrix NeoFlex features a new advanced stent delivery system, improving pushability, trackability, and crossability. It also has a lower lesion entry profile than its predecessor. BioMatrix NeoFlex retains the same combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9, and platform that has made the BioMatrix stent family an increasingly popular choice of DES in global markets where available.
CardioDx Announces Publication of the IMPACT-CARD Trial Demonstrating Use of Corus@ CAD Test Influenced Cardiologists' Clinical Management of Patients with Symptoms Suggestive of Obstructive Coronary Artery DiseaseMay 20, 2013 8:31 am | by The Associated Press | News | Comments
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective...
Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark and will soon be launched in Europe and other international markets.
OrbusNeich's GenousT Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) PatientsMay 20, 2013 5:00 am | by The Associated Press | News | Comments
OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an...
Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVRMay 19, 2013 1:43 pm | by Bio-Medicine.Org | News | Comments
SANTA ROSA, Calif. , May 20, 2013 /- Claret Medical, Inc. announced the publication of an original manuscript by Dr. Nicolas Van Mieghem et al., Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement . Published ahead of print in Circulation, May 7 th this research is the result of a collaboration between Erasmus Medical Center, Rotterdam,
Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more complicated than drug trails due to their unique clinical practices....
This article will walk through the various characteristics of these resistors, including high resistance values, high voltage handling, small size, resiliency, and more, to demonstrate how they might aid in the design of medical devices.
The type of sensors that pick up the rhythm of a beating heart in implanted cardiac defibrillators and pacemakers are vulnerable to tampering, according to a new study conducted in controlled laboratory conditions. Implantable defibrillators monitor the heart for irregular beating and, when necessary, administer an electric shock to bring it back into normal rhythm.
An experimental, inexpensive iPhone application transmitted diagnostic heart images faster and more reliably than emailing photo images, according to a research study presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.
CardioDx Announces New Data Demonstrating Use of Corus® CAD in the Primary Care Setting for Evaluation of Symptomatic Patients with Suspected CAD Influences Clinical Decision MakingMay 17, 2013 11:00 am | by PR Newswire | News | Comments
PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a clinical utility study of the Corus® CAD gene expression test in the real-world primary care setting for evaluating patients with...
PLEASANTON, Calif., May 17, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it has received approval from the U.S. Food and Drug...
Valtech Cardio Treats First Mitral Regurgitation Patients with Percutaneous Annuloplasty Device Without Open-Heart SurgeryMay 16, 2013 2:14 pm | by PR Newswire | News | Comments
Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully with the Transfemoral Cardioband™ Annuloplasty System.
Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT StentMay 16, 2013 10:03 am | by Tryton Medical | News | Comments
Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options in bifurcations in large vessels with a short main branch landing zone.
Engineers combine layers of flexible materials into pressure sensors to create a wearable heart monitor thinner than a dollar bill. The skin-like device could one day provide doctors with a safer way to check the condition of a patient's heart.